BioSpace News Archive

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021.

Lennham Pharmaceuticals, a privately-held company focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced the discovery and patenting of its next generation testosterone candidate, d3-testosterone.

The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently recognized 41 women scientists who received a record-breaking $541,000 in research funding this year.

PathAI, a global leader of AI-powered technology applied to pathology, today announced new data showing AI-based assessment, including use of PathAI’s AIM-NASH tool, of key histological features of non-alcoholic steatohepatitis (NASH) following semaglutide treatment.

Clinical studies demonstrate the considerable patient benefits of the vaginal natural orifice transluminal endoscopic surgery technique – a new, modern approach to vaginal surgery.

Novoic Ltd, a clinical stage digital medtech company developing speech- and language-based biomarkers for neurological disease, has presented a scientific symposium together with the Alzheimer’s Drug Discovery Foundation’s Diagnostic Accelerator at the 14th Annual Clinical Trials on Alzheimer’s Disease in Boston, MA, USA.

Genmab Announces Financial Results for the First Nine Months of 2021

LYON, France, November 10, 2021 - EDAP TMS SA, the global leader in therapeutic ultrasound, announced that it will release its financial results for the third quarter ended September 30, 2021 after the markets close on Wednesday, November 17, 2021.

Pyxis Oncology, Inc., announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Hepion Pharmaceuticals, Inc. today announced that results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of the Company’s lead drug candidate, CRV431, will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually November 12-15, 2021.